Laurus Labs (BOM:540222) 3-Year EBITDA Growth Rate : -20.00% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Laurus Labs 3-Year EBITDA Growth Rate?

Laurus Labs's EBITDA per Share for the three months ended in Mar. 2024 was ₹4.80.

During the past 12 months, Laurus Labs's average EBITDA Per Share Growth Rate was -49.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -20.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 22.20% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 19.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Laurus Labs was 57.30% per year. The lowest was -20.00% per year. And the median was 22.15% per year.

Competitive Comparison of Laurus Labs's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laurus Labs's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Laurus Labs's 3-Year EBITDA Growth Rate falls into.

Laurus Labs 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Laurus Labs (BOM:540222) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Laurus Labs 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Laurus Labs's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Laurus Labs (BOM:540222) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Laurus Labs Ltd (BOM:540222) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

LAURUSLABS:India

Address

Road No. 7, Banjara Hills, 2nd Floor, Serene Chambers, Hyderabad, TG, IND, 500034

Website

https://www.lauruslabs.com

Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceuticals ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services and others.

Laurus Labs (BOM:540222) Headlines

No Headlines